Keywords: revlimid, combo, become, mm, standard, care, drugmaker

Revlimid combo could become MM standard of care

Article | 18 June 2007

Print This

US drugmaker Celgene presented positive data from a Phase I/II study evaluating a combination of Revlimid (lenalidomide), melphalan and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in